INVERSAGO-PHARMA
7.9.2021 14:02:05 CEST | Business Wire | Press release
Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced that following the receipt of a No Objection Letter (NOL) from Health Canada on July 29, 2021, it has dosed the first volunteers with INV-202 in its first-in-human phase 1 clinical trial, which will evaluate the safety, tolerability and pharmacokinetics of this compound.
As a next generation peripheral CB1 inverse agonist / antagonist, INV-202 has the potential to treat various metabolic conditions such as Prader-Willi Syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes (T1D), diabetic nephropathy and chronic kidney diseases, among others.
“Having demonstrated pharmacological characteristics that exceeded our expectations during IND-enabling preclinical studies, we’re excited to launch a second peripherally-acting CB1 blocker into the clinic with INV-202,” said Dr. Glenn Crater, MD, Chief Medical Officer of Inversago Pharma.
“With two unique, next generation CB1 blockers having entered the clinic in less than a year, we are rapidly bolstering our knowledge of this new class of drugs, which we believe may provide new treatment options for patients affected by a range of metabolic conditions,” said François Ravenelle, PhD, Chief Executive Officer of Inversago.
About INV-202
INV-202 is a small molecule CB1 inverse agonist / antagonist being developed by Inversago for the potential treatment of several metabolic conditions. It is specifically designed to preferentially interact with peripheral CB1 receptors located in the gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs, thus aiming at a safe and effective therapeutic approach without the known liabilities of centrally-acting CB1 blockers. The peripheral CB1 blockade is a well-documented pathway, linked to many clinically meaningful metabolic benefits.
About Inversago Pharma
Headquartered in Montreal, Inversago Pharma is a clinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as PWS, NASH, T1D and diabetic nephropathy. For more information, visit inversago.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005183/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HeadFirst Global Becomes Vertage, Uniting 11 Businesses in a Single Work Orchestration Platform24.9.2026 01:01:00 CEST | Press release
HeadFirst Global, a €10 billion group comprised of Impellam and HeadFirst Group,unites 11 businesses under Vertage, a single name, platform, and operating model Platform will curate the right mix of expert talent and AI agents to deliver work outcomes for enterprise customers across Americas, the UK and Europe, and Asia Pacific Operating brands retire in Q1 2027. Existing contracts, delivery teams, and day-to-day contacts continue unchanged through the transition HeadFirst Global, a leader in work orchestration, today announced it will become Vertage, as it builds a global technology platform that dynamically curates the right mix of expert talent and AI agents to deliver the work outcomes enterprises need. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260923823506/en/ Edzard Overbeek, Group CEO at Vertage The €10 billion group is bringing its 11 operating businesses together under the Vertage name, platform, and operating
Grid Dynamics Co-Hosts Physical AI Summit Alongside NVIDIA, EAIGG, and BGV to Accelerate Manufacturing Automation23.9.2026 22:05:00 CEST | Press release
Key Takeaways: Grid Dynamics joins NVIDIA, EAIGG, and BGV as co-hosts of the invite-only Physical AI Summit, bringing together leaders from enterprises, Physical AI startups, and investors on September 24, 2026, at the Wells Fargo Innovation Center in Menlo Park, CA. The summit, themed "From World Models to Real-World Control," focuses on moving Physical AI beyond demos and pilots into production across manufacturing, CPG, logistics, and retail. Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (“Grid Dynamics”), a premier AI transformation partner for the Fortune 1000, announced today that it is co-hosting the Physical AI Summit alongside NVIDIA, EAIGG, and BGV. The invite-only working forum will bring together participants from enterprises, Physical AI startups, and investors on September 24, 2026, at the Wells Fargo Innovation Center in Menlo Park, CA. Centered on the theme "From World Models to Real-World Control," the summit will focus on the practical challenges of deploying, scaling,
Liquid AI, in Collaboration with Qualcomm Technologies, Brings Personal AI Context to Devices Powered by Snapdragon23.9.2026 21:00:00 CEST | Press release
Liquid AI today, at Snapdragon Summit 2026, announced that Liquid Context, an on-device context layer, is now optimized for Snapdragon® processors, specifically using the Qualcomm® Hexagon™ NPU. In collaboration with Qualcomm Technologies, Liquid Context built a persistent understanding of the user from signals from devices with Snapdragon processors and made relevant context available to AI agents, whether they ran on the device, in the cloud or across both. Device manufacturers now have a foundation for more proactive, personalized and trustworthy AI experiences, alongside Liquid Agent, Liquid AI’s efficient embedded agent. Personal Context That Makes Any Agent More Useful Useful agents need to understand what matters to the user and when help is needed. With the user’s permission, Liquid Context learns from device signals, builds an understanding of routines, preferences and needs, and keeps that understanding current. It provides a shared context layer between the device and the us
Doha Debates Podcast Returns for a New Season Exploring the Ideas Shaping Our World23.9.2026 19:29:00 CEST | Press release
The 20-episode season, launched September 22, builds on questions raised in flagship debates and global town halls through long-form conversations. Qatar Foundation’s Doha Debates has launched a new season of the Doha Debates Podcast, with 20 episodes airing weekly through February 16, 2027. The series brings leading global thinkers together to debate some of the world’s most complex and challenging issues. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260923050361/en/ Doha Debates Podcast Returns for a New Season (Photo: AETOSWire) The podcast carries forward themes from its flagship debates and town halls through long-form conversations, reflecting Doha Debates’ commitment to open, truth-seeking dialogue exploring global issues with depth, nuance and respect for diverse perspectives. The opening episode, “Will China or the West lead the world into the future?” moderated by Soraya Salam, brings together Renata Ávila, CEO o
Dryad Wins International XPRIZE Wildfire Award for Autonomous Wildfire Detection and Suppression23.9.2026 19:00:00 CEST | Press release
European finalist demonstrates ultra-early wildfire detection with Silvanet and autonomous suppression with Silvaguard Dryad Networks, a leader in ultra-early wildfire detection, today announced it has been awarded $800,000 in the XPRIZE Wildfire competition for its performance in the Autonomous Wildfire Response finals in Alaska. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260923024178/en/ Silvaguard Observation and Suppression drone and Hangar Dryad advanced from an original field of approximately 300 entrants in the four-year competition. In June 2026, three finalists were challenged to autonomously detect and completely suppress a high-risk wildfire within 10 minutes of ignition across 1,000 km² of Alaskan wilderness, leaving any decoy fires untouched. It was the most demanding live test to date of what it will take to stop a destructive fire before it grows out of control. During the tests, the Dryad’s Silvanet senso
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom